PLAUR and focal segmental glomerulosclerosis: Soluble uPAR (suPAR), the ectodomains of uPAR, becomes a risk factor in a number of human clinical indications, including chronic and systemic inflammation10, focal segmental glomerulosclerosis (FSGS)11,12, acute kidney injury (AKI)13,14, chronic kidney disease (CKD)15 and diabetes16,17.